All Stories

  1. Clinical Advances and Perspectives in Targeted Radionuclide Therapy
  2. Clinical Advances and Perspectives in Targeted Radionuclide Therapy
  3. 188Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study)
  4. Hepatotropic Peptides Grafted onto Maleimide-Decorated Nanoparticles: Preparation, Characterization and In Vitro Uptake by Human HepaRG Hepatoma Cells
  5. Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl malate)-Based Nanoparticles in Human Hepatoma Cells
  6. Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?
  7. Receptor-Specific Radionuclide Therapy
  8. Tuning the lipophilic nature of pyclen-based 90Y3+ radiopharmaceuticals for β-radiotherapy
  9. Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma
  10. Comparison of [68Ga]Ga precursors for blood cell radiolabeling
  11. Synthesis of Poly(Malic Acid) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells
  12. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
  13. 188Re-SSS/Lipiodol for HCC treatment: from (radio)chemistry to preliminary clinical results
  14. Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives
  15. Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization
  16. Review on potential therapeutic modalities for liver cancers
  17. Cell Uptake and Biocompatibility of Nanoparticles Prepared from Poly(benzyl malate) (Co)polymers Obtained through Chemical and Enzymatic Polymerization in Human HepaRG Cells and Primary Macrophages
  18. Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells
  19. Stable and Inert Yttrium(III) Complexes with Pyclen-Based Ligands Bearing Pendant Picolinate Arms: Toward New Pharmaceuticals for β-Radiotherapy
  20. Design, Synthesis, and Reactivity of Multidentate Ligands with Rhenium(I) and Rhenium(V) Cores
  21. Transarterial Radionuclide Therapy with 188Re-Labelled Lipiodol
  22. Automatisation de la production de nanocapsules lipidiques chargées en technétium-99 m
  23. Locoregional Confinement and Major Clinical Benefit of 188Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
  24. The role of the capping bond effect on pyclen natY3+/90Y3+ chelates: full control of the regiospecific N-functionalization makes the difference
  25. Rhenium Complexes Based on an N2O Tridentate Click Scaffold: From Synthesis, Structural and Theoretical Characterization to a Radiolabelling Study
  26. Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model
  27. 68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies
  28. Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to 90Y Radiolabeling
  29. Microparticules à base d’amidon radiomarquées au 188Re et 68Ga comme agent théranostique pour la radiothérapie interne sélective du carcinome hépatocellulaire
  30. Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization
  31. Main applications of hybrid PET-MRI contrast agents: a review
  32. Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability
  33. Radiopharmaceutcials radiolabelled with 188Re as potential therapeutic tools for hepatocellular carcinoma targeting
  34. Development of Biocompatible and Functional Polymeric Nanoparticles for Site-Specific Delivery of Radionuclides
  35. Biodistribution et toxicité des nanocapsules chargées en 188Re après injection intratumorale par convection enhanced delivery chez la souris
  36. Escalade de dose et efficacité des nanocapsules chargées en 188Re dans un modèle d’adénocarcinome de l’endomètre chez la souris
  37. Mixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinoma
  38. 120: From bench to bedside: development and early clinical results of 188Re-SSS/Lipiodol for HCC treatment
  39. Optimization of Hepatocarcinoma Uptake with Radiolabeled Lipiodol: Development of New Lipiodol Formulations with Increased Viscosity
  40. Reduction of β-radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatment
  41. -SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside
  42. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with 188Re-lipid nanocapsules
  43. Lipid Nanocapsules Loaded with Rhenium-188 Reduce Tumor Progression in a Rat Hepatocellular Carcinoma Model
  44. Automation of labelling of Lipiodol with high-activity generator-produced 188Re
  45. Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen
  46. Labeling Techniques with 123I
  47. 188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas
  48. Therapy of Hepatocellular Carcinoma with Rhenium-188 Lipiodol
  49. Spectroscopic Investigations of Fine‐Tuned Energy Differences in a Series of Substituted Rhenium and Technetium Complexes [M(RPhCS3)2(RPhCS2)] {M=Re,99Tc; R=H, F, Me, Et, OMe}
  50. Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat
  51. Effect of Stabilized Iodized Oil Emulsion on Experimentally Induced Hepatocellular Carcinoma in Rats
  52. Syntheses and reactivity of ‘sulfur rich’ Re(iii) and Tc(iii) complexes containing trithioperoxybenzoate, dithiobenzoate and dithiocarbamate ligands
  53. A kit formulation for the labelling of lipiodol with generator-produced188Re
  54. 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma
  55. Development and biodistribution of 188 Re-SSS lipiodol following injection into the hepatic artery of healthy pigs
  56. Development of 99mTc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig
  57. Chelated Hydrazido(3−)rhenium(V) Complexes:  On the Way to the Nitrido−M(V) Core (M = Tc, Re)